On this page
CALM2
calmodulin 2
CALM2 encodes calmodulin, a calcium-binding protein that regulates cardiac electrical activity and muscle contraction in response to intracellular calcium signals. The CALM2 gene provides instructions for making calmodulin, one of three nearly identical calmodulin proteins in human cells.
CALM2 is located on the short (p) arm of chromosome 2, at band 2p21. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 2 in the library →Overview
The CALM2 gene is one of three human genes that encode calmodulin, a highly conserved calcium-binding protein essential for translating intracellular calcium signals into biological responses. The three calmodulin genes (CALM1, CALM2, and CALM3) are located on different chromosomes but produce functionally identical proteins, reflecting the critical importance of calmodulin to cellular function. This genetic redundancy ensures that cells maintain adequate calmodulin levels even when one gene is compromised.
Calmodulin is particularly vital for cardiac muscle cells, where it regulates ion channels and proteins that control the heart's electrical rhythm. Pathogenic variants in CALM2 can impair the protein's calcium-binding ability, disrupting cardiac electrical signalling and causing potentially fatal arrhythmias. Because of the severe cardiac risks associated with CALM2 variants, this gene is included in the American College of Medical Genetics and Genomics Secondary Findings list, meaning laboratories may report clinically actionable variants even when testing was requested for an unrelated indication.
What the gene does
Calmodulin functions as a multifunctional intermediate messenger protein that detects calcium signals and transmits them to downstream cellular targets. When calcium ions enter the cell, they bind to calmodulin, causing a conformational change that allows the protein to interact with and modulate more than 100 different target proteins. This calcium-calmodulin regulatory system controls diverse processes including muscle contraction, neurotransmitter release, cell cycle progression, and gene transcription.
In cardiac muscle cells, calmodulin plays an especially critical role in regulating electrical activity. The protein modulates several key ion channels and transporters, including L-type calcium channels, sodium channels, and ryanodine receptors that control calcium release from intracellular stores. Calmodulin's interaction with these targets helps coordinate the precise timing of cardiac muscle contraction and relaxation during each heartbeat. The protein also regulates calcium/calmodulin-dependent protein kinase II, an enzyme that phosphorylates numerous cardiac proteins to fine-tune electrical and contractile properties.
Each calmodulin protein can bind up to four calcium ions through specialised structural motifs. The calcium-binding process occurs in a stepwise fashion, with each binding event increasing the protein's affinity for target molecules. This cooperative binding mechanism allows calmodulin to function as a sensitive calcium concentration detector, responding to the rapid fluctuations in calcium levels that occur during cellular signalling events.
Video: Genetics 101
Chromosome location
The CALM2 gene is located on the short arm of chromosome 2 at position 2p21. The gene spans a relatively compact genomic region and contains six exons that are transcribed and spliced to produce the calmodulin messenger RNA. The coding sequence encompasses 450 base pairs, directing synthesis of a 149-amino-acid protein. Despite being on different chromosomes, CALM1, CALM2, and CALM3 share nearly identical coding sequences, producing proteins that differ by at most a single amino acid and are functionally interchangeable in most contexts.
Protein structure
The calmodulin protein comprises 149 amino acids organised into four calcium-binding motifs known as EF-hand domains. EF-hand 1 encompasses amino acids 8-43, followed by EF-hand 2 covering positions 44-79. The third EF-hand spans approximately amino acids 81-116, whilst EF-hand 4 extends from position 117 to 149. Each EF-hand consists of a helix-loop-helix structure where the loop region coordinates a calcium ion through oxygen atoms from acidic amino acid side chains.
The four EF-hands are arranged in two pairs connected by a flexible central linker region. This organisation creates a dumbbell-shaped molecule with calcium-binding lobes at each end. When calcium binds, the EF-hands undergo conformational changes that expose hydrophobic surfaces, allowing calmodulin to wrap around target proteins. The region spanning amino acids 77-149, which includes the second pair of EF-hands, is necessary and sufficient for interaction with certain binding partners such as PCP4. This modular architecture allows calmodulin to adopt different conformations depending on calcium concentration and the specific target protein being engaged.
Key variants
Pathogenic variants in CALM2 typically affect the protein's calcium-binding capacity or alter its ability to interact with downstream targets. Because the calmodulin protein sequence is highly conserved across species and among the three human calmodulin genes, even single amino acid substitutions can have profound functional consequences. Most disease-causing variants are missense changes that disrupt the precise geometry required for calcium coordination within the EF-hand domains.
The majority of clinically significant CALM2 variants are heterozygous, meaning they affect only one of the two gene copies. However, because calmodulin functions as a sensor that must accurately detect calcium concentrations, even a single abnormal copy can disrupt calcium signalling, potentially through haploinsufficiency or altered functional properties that interfere with normal calcium sensing. The variant landscape in CALM2 continues to expand as genetic testing becomes more widespread for individuals with unexplained cardiac arrhythmias.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.286G>T | p.Asp96Tyr | Pathogenic/Likely pathogenic | ★★☆☆ | Long QT syndrome 15 |
c.287A>T | p.Asp96Val | Pathogenic | ★★☆☆ | Long QT syndrome 1 |
c.293A>G | p.Asn98Ser | Pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.293A>T | p.Asn98Ile | Pathogenic | ★☆☆☆ | Long QT syndrome 1 |
c.388G>A | p.Asp130Asn | Pathogenic | ★☆☆☆ | Long QT syndrome 1 |
c.389A>G | p.Asp130Gly | Pathogenic | ★☆☆☆ | Long QT syndrome 1 |
c.394G>T | p.Asp132Tyr | Pathogenic | ★☆☆☆ | Long QT syndrome 1 |
c.395A>G | p.Asp132Gly | Pathogenic | ★☆☆☆ | Long QT syndrome 1 |
c.396T>G | p.Asp132Glu | Pathogenic | ★☆☆☆ | Long QT syndrome 15 |
c.414C>G | p.Asn138Lys | Pathogenic | ★☆☆☆ | Long QT syndrome 15 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in CALM2 are associated with severe cardiac arrhythmia syndromes that typically manifest in childhood or adolescence. The two primary conditions linked to CALM2 variants are long QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Both disorders involve abnormal heart rhythms that can cause fainting, seizures, or sudden cardiac death, particularly during physical exertion or emotional stress. These conditions arise because defective calmodulin cannot properly regulate cardiac ion channels, leading to prolonged or unstable electrical recovery phases in heart muscle cells. Early identification through genetic testing allows for preventive interventions including beta-blocker medications, lifestyle modifications, and in some cases implantable cardioverter-defibrillators.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic CALM2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
Within the NHS Genomic Medicine Service, CALM2 appears on current NHS panels with green classification status, indicating strong evidence for clinical validity. The gene is included in cardiovascular gene panels such as the Catecholaminergic Polymorphic VT panel and the Long QT Syndrome panel. Green classification means that CALM2 variants are routinely analysed when these panels are requested for patients with relevant clinical presentations. Testing is typically coordinated through specialist cardiac genetics services, often involving multidisciplinary teams including cardiologists, genetic counsellors, and clinical geneticists who can interpret results in the context of personal and family cardiac history.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with pathogenic CALM2 variants, certain lifestyle modifications may help reduce the risk of arrhythmic events, though all decisions should be made in consultation with a cardiac specialist. Research in long QT syndrome and catecholaminergic polymorphic ventricular tachycardia suggests that vigorous physical activity and competitive sports can increase the risk of arrhythmic events in susceptible individuals. Swimming has been particularly associated with events in some long QT subtypes, though the relationship varies by genetic cause.
Maintaining adequate hydration and electrolyte balance appears important for cardiac electrical stability in the general population. Some studies indicate that sudden loud noises may provoke arrhythmic events in people with certain forms of long QT syndrome (though not all genetic causes respond identically), leading some specialists to recommend gentler awakening methods. Avoiding medications known to prolong the QT interval is typically advised, and individuals should inform all healthcare providers about their genetic status when new medications are being considered. Stress management techniques may also be beneficial, as emotional stress can trigger arrhythmias in susceptible individuals.
Supplement considerations
There is no conclusive evidence that any dietary supplement prevents cardiac arrhythmias in individuals with CALM2 variants. Whilst calcium and magnesium are essential minerals for normal cardiac electrical function in the general population, supplementation beyond recommended dietary allowances has not been shown to reduce arrhythmia risk in people with genetic ion channel disorders. Some preliminary research has examined whether omega-3 fatty acids might have anti-arrhythmic properties, but results remain inconclusive and cannot be extrapolated to genetically determined arrhythmia syndromes.
Anyone with a pathogenic CALM2 variant should discuss any supplement use with their cardiologist or healthcare provider before starting, as some supplements can interact with prescribed medications or potentially affect cardiac electrical activity. Potassium supplementation, for instance, requires careful medical supervision in people with cardiac rhythm disorders. The primary management for CALM2-related conditions relies on established medical interventions rather than nutritional supplementation.
Frequently asked questions
Why are there three calmodulin genes if they make the same protein?
The three calmodulin genes (CALM1, CALM2, and CALM3) represent an example of genetic redundancy that ensures cells always produce adequate amounts of this essential protein. Because calmodulin is required for so many fundamental cellular processes, having three separate genes on different chromosomes provides backup in case one gene is damaged or mutated.
Can CALM2 variants cause sudden cardiac death in young people?
Yes, pathogenic variants in CALM2 can cause life-threatening cardiac arrhythmias that may result in sudden cardiac death, particularly in children and young adults. However, with appropriate medical management including beta-blockers and sometimes implantable defibrillators, risk can be substantially reduced.
How is CALM2 testing different from standard cardiac genetic testing?
CALM2 is typically included as part of comprehensive gene panels for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia. Because pathogenic variants in CALM2 are relatively rare compared to more common arrhythmia genes, testing is usually performed using multi-gene panels rather than single-gene analysis.
If I have a CALM2 variant, will my children inherit it?
CALM2-related conditions follow an autosomal dominant pattern, meaning each child of an affected individual has a 50% chance of inheriting the variant. However, inheritance of the variant does not guarantee identical symptoms, as disease severity can vary even within families.
Are CALM2 variants more common in certain populations?
Current evidence does not indicate that pathogenic CALM2 variants are concentrated in specific ethnic or geographic populations. These variants appear to arise spontaneously and are distributed broadly, though the overall frequency of disease-causing CALM2 variants remains low in the general population.